Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients
Immunotherapy for melanoma includes adoptive cell therapy with autologous tumor-infiltrating lymphocytes (TILs). This monocenter retrospective study was undertaken to evaluate the efficacy and safety of this treatment of patients with advanced melanoma. All advanced melanoma patients treated with TI...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2018/3530148 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832556545974468608 |
|---|---|
| author | Mélanie Saint-Jean Anne-Chantal Knol Christelle Volteau Gaëlle Quéreux Lucie Peuvrel Anabelle Brocard Marie-Christine Pandolfino Soraya Saiagh Jean-Michel Nguyen Christophe Bedane Nicole Basset-Seguin Amir Khammari Brigitte Dréno |
| author_facet | Mélanie Saint-Jean Anne-Chantal Knol Christelle Volteau Gaëlle Quéreux Lucie Peuvrel Anabelle Brocard Marie-Christine Pandolfino Soraya Saiagh Jean-Michel Nguyen Christophe Bedane Nicole Basset-Seguin Amir Khammari Brigitte Dréno |
| author_sort | Mélanie Saint-Jean |
| collection | DOAJ |
| description | Immunotherapy for melanoma includes adoptive cell therapy with autologous tumor-infiltrating lymphocytes (TILs). This monocenter retrospective study was undertaken to evaluate the efficacy and safety of this treatment of patients with advanced melanoma. All advanced melanoma patients treated with TILs using the same TIL expansion methodology and same treatment interleukin-2 (IL-2) regimen between 2009 and 2012 were included. After sterile intralesional excision of a cutaneous or subcutaneous metastasis, TILs were produced according to a previously described method and then infused into the patient who also received a complementary subcutaneous IL-2 regimen. Nine women and 1 man were treated for unresectable stage IIIC (n=4) or IV (n=6) melanoma. All but 1 patient with unresectable stage III melanoma (1st line) had received at least 2 previous treatments, including anti-CTLA-4 antibody for 4. The number of TILs infused ranged from 0.23 × 109 to 22.9 × 109. Regarding safety, no serious adverse effect was reported. Therapeutic responses included a complete remission, a partial remission, 2 stabilizations, and 6 progressions. Among these 4 patients with clinical benefit, 1 is still alive with 9 years of follow-up and 1 died from another cause after 8 years of follow-up. Notably, patients treated with high percentages of CD4 + CD25 + CD127lowFoxp3+ T cells among their TILs had significantly shorter OS. The therapeutic effect of combining TILs with new immunotherapies needs further investigation. |
| format | Article |
| id | doaj-art-36f49e1a78814611842a3f33a76fcd99 |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-36f49e1a78814611842a3f33a76fcd992025-02-03T05:44:59ZengWileyJournal of Immunology Research2314-88612314-71562018-01-01201810.1155/2018/35301483530148Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma PatientsMélanie Saint-Jean0Anne-Chantal Knol1Christelle Volteau2Gaëlle Quéreux3Lucie Peuvrel4Anabelle Brocard5Marie-Christine Pandolfino6Soraya Saiagh7Jean-Michel Nguyen8Christophe Bedane9Nicole Basset-Seguin10Amir Khammari11Brigitte Dréno12Dermato-cancerology Department, CHU Nantes, Place Alexis Ricordeau, 44093 Nantes, FranceCIC1413, CRCINA INSERM U1232, CHU Nantes, Place Alexis Ricordeau, Nantes, FranceResearch Leading Department, CHU Nantes, Place Alexis Ricordeau, 44093 Nantes, FranceDermato-cancerology Department, CHU Nantes, Place Alexis Ricordeau, 44093 Nantes, FranceDermato-cancerology Department, CHU Nantes, Place Alexis Ricordeau, 44093 Nantes, FranceDermato-cancerology Department, CHU Nantes, Place Alexis Ricordeau, 44093 Nantes, FranceCell and Gene Therapy Unit, CHU Nantes, Place Alexis Ricordeau, 44093 Nantes, FranceCell and Gene Therapy Unit, CHU Nantes, Place Alexis Ricordeau, 44093 Nantes, FranceSEME, CIC1413, CRCINA INSERM U1232, CHU Nantes, Place Alexis Ricordeau, Nantes, FranceDermatology Department, University Hospital, 2 avenue Martin Luther King, 87042 Limoges Cedex, FranceDermatology Department, Saint-Louis Hospital, 1 avenue Claude-Vellefaux, 75475 Paris Cedex 10, FranceDermato-cancerology Department, CHU Nantes, Place Alexis Ricordeau, 44093 Nantes, FranceDermato-cancerology Department, CHU Nantes, Place Alexis Ricordeau, 44093 Nantes, FranceImmunotherapy for melanoma includes adoptive cell therapy with autologous tumor-infiltrating lymphocytes (TILs). This monocenter retrospective study was undertaken to evaluate the efficacy and safety of this treatment of patients with advanced melanoma. All advanced melanoma patients treated with TILs using the same TIL expansion methodology and same treatment interleukin-2 (IL-2) regimen between 2009 and 2012 were included. After sterile intralesional excision of a cutaneous or subcutaneous metastasis, TILs were produced according to a previously described method and then infused into the patient who also received a complementary subcutaneous IL-2 regimen. Nine women and 1 man were treated for unresectable stage IIIC (n=4) or IV (n=6) melanoma. All but 1 patient with unresectable stage III melanoma (1st line) had received at least 2 previous treatments, including anti-CTLA-4 antibody for 4. The number of TILs infused ranged from 0.23 × 109 to 22.9 × 109. Regarding safety, no serious adverse effect was reported. Therapeutic responses included a complete remission, a partial remission, 2 stabilizations, and 6 progressions. Among these 4 patients with clinical benefit, 1 is still alive with 9 years of follow-up and 1 died from another cause after 8 years of follow-up. Notably, patients treated with high percentages of CD4 + CD25 + CD127lowFoxp3+ T cells among their TILs had significantly shorter OS. The therapeutic effect of combining TILs with new immunotherapies needs further investigation.http://dx.doi.org/10.1155/2018/3530148 |
| spellingShingle | Mélanie Saint-Jean Anne-Chantal Knol Christelle Volteau Gaëlle Quéreux Lucie Peuvrel Anabelle Brocard Marie-Christine Pandolfino Soraya Saiagh Jean-Michel Nguyen Christophe Bedane Nicole Basset-Seguin Amir Khammari Brigitte Dréno Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients Journal of Immunology Research |
| title | Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients |
| title_full | Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients |
| title_fullStr | Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients |
| title_full_unstemmed | Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients |
| title_short | Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients |
| title_sort | adoptive cell therapy with tumor infiltrating lymphocytes in advanced melanoma patients |
| url | http://dx.doi.org/10.1155/2018/3530148 |
| work_keys_str_mv | AT melaniesaintjean adoptivecelltherapywithtumorinfiltratinglymphocytesinadvancedmelanomapatients AT annechantalknol adoptivecelltherapywithtumorinfiltratinglymphocytesinadvancedmelanomapatients AT christellevolteau adoptivecelltherapywithtumorinfiltratinglymphocytesinadvancedmelanomapatients AT gaellequereux adoptivecelltherapywithtumorinfiltratinglymphocytesinadvancedmelanomapatients AT luciepeuvrel adoptivecelltherapywithtumorinfiltratinglymphocytesinadvancedmelanomapatients AT anabellebrocard adoptivecelltherapywithtumorinfiltratinglymphocytesinadvancedmelanomapatients AT mariechristinepandolfino adoptivecelltherapywithtumorinfiltratinglymphocytesinadvancedmelanomapatients AT sorayasaiagh adoptivecelltherapywithtumorinfiltratinglymphocytesinadvancedmelanomapatients AT jeanmichelnguyen adoptivecelltherapywithtumorinfiltratinglymphocytesinadvancedmelanomapatients AT christophebedane adoptivecelltherapywithtumorinfiltratinglymphocytesinadvancedmelanomapatients AT nicolebassetseguin adoptivecelltherapywithtumorinfiltratinglymphocytesinadvancedmelanomapatients AT amirkhammari adoptivecelltherapywithtumorinfiltratinglymphocytesinadvancedmelanomapatients AT brigittedreno adoptivecelltherapywithtumorinfiltratinglymphocytesinadvancedmelanomapatients |